Structure–Activity Relationship Studies toward the Optimization of First-In-Class Selective Small Molecule Agonists of the GPCR Relaxin/Insulin-like Family Peptide Receptor 2

A dose-response quantitative high-throughput screening of 147,334 small molecule compounds using a human Relaxin/Insulin-like Family Peptide Receptor 2 (RXFP2)-transfected HEK293T-RXFP2 cell line identified compound <b>5</b> with modest Insulin-Like3 (INSL3) agonist activity. An extensive structure-activity relationship (SAR) study was undertaken to improve potency, efficacy, and physical/metabolic properties of the series, resulting in the discovery of compound <b>68</b>. This compound represents the first-in-class small molecule full agonist of RXFP2 that exhibits nanomolar potency and favorable pharmacokinetic characteristics, including high systemic exposure in vivo. Based on these findings, compound <b>68</b> was selected as the lead preclinical candidate for investigating the role of RXFP2 activation in bone remodeling and other physiological systems in vitro and in vivo<i>.</i>

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2026-02-19
DOI
https://doi.org/10.1021/acs.jmedchem.5c03387
Primary Topic
Pregnancy-related medical research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Structure–Activity Relationship Studies toward the Optimization of First-In-Class Selective Small Molecule Agonists of the GPCR Relaxin/Insulin-like Family Peptide Receptor 2

Konstantinos Afratis, Emmett R. George, Irina U. Agoulnik, María Esteban-López et al.
Journal of Medicinal Chemistry
Pregnancy-related medical research
article

Structure–Activity Relationship Studies toward the Optimization of First-In-Class Selective Small Molecule Agonists of the GPCR Relaxin/Insulin-like Family Peptide Receptor 2

Konstantinos Afratis, Emmett R. George, Irina U. Agoulnik, María Esteban-López, Christopher A. LeClair, Marc Ferrer, Wenjuan Ye, Elias Carvalho Padilha, Juan Marugán, Elena Barnaeva, David Calabrese, Kenneth J. Wilson, Mark J. Henderson, Abhijeet Kapoor, Samuel A. Kotler, Pranav Shah, Courtney B. Myhr, Alexander Kushnir, Yuhong Fang, Curtis E. Moore, Xin Hu, Noel Southall, Amy Wang, Xin Xu
article en

Abstract

A dose-response quantitative high-throughput screening of 147,334 small molecule compounds using a human Relaxin/Insulin-like Family Peptide Receptor 2 (RXFP2)-transfected HEK293T-RXFP2 cell line identified compound <b>5</b> with modest Insulin-Like3 (INSL3) agonist activity. An extensive structure-activity relationship (SAR) study was undertaken to improve potency, efficacy, and physical/metabolic properties of the series, resulting in the discovery of compound <b>68</b>. This compound represents the first-in-class small molecule full agonist of RXFP2 that exhibits nanomolar potency and favorable pharmacokinetic characteristics, including high systemic exposure in vivo. Based on these findings, compound <b>68</b> was selected as the lead preclinical candidate for investigating the role of RXFP2 activation in bone remodeling and other physiological systems in vitro and in vivo<i>.</i>

Journal of Medicinal ChemistryVol. 69(5)
National Institutes of Health (US), Florida International University (US), University of South Florida (US), National Center for Advancing Translational Sciences (US), The Ohio State University (US)
Openalex Percentile: Top 53%
Pregnancy-related medical research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.